Gilead Sciences(NASDAQ) GILD

Gilead Sciences, Inc. makes medicines to treat life-threatening illnesses. These treatments help people managing HIV, liver disease, and cancer. Its drugs also treat hospitalized patients fighting viral infections.

Fighting Life-Threatening Diseases

• HIV: Supplies therapies like Biktarvy and Descovy; accounted for $5.7 billion in product sales for the three months ended June 30, 2026.
• Oncology: Focuses on breast and lung cancer treatments; recorded $873 million in product sales for the three months ended June 30, 2026.
• Liver Disease: Includes treatments for hepatitis B, C, and D; contributed $877 million in product sales for the three months ended June 30, 2026.
• Veklury: Injectable medication used for patients hospitalized with COVID-19; generated $23 million in product sales for the three months ended June 30, 2026.

Acquisitions and Pipeline Shifts

• Acquired Arcellx in 2026 to develop cell therapies for blood cancers like multiple myeloma.
• Purchased Tubulis in 2026 to gain next-generation antibody-drug conjugates, which are targeted cancer-fighting molecules.
• Acquired Ouro Medicines in 2026 to expand the inflammation portfolio with treatments for autoimmune diseases.
• Discontinued the Phase 3 clinical study of Trodelvy in patients with lung cancer in June 2026.

A Global Scientific Footprint

Gilead operates in more than 35 countries and manages its worldwide business from headquarters in California. The company partners with external research organizations to develop treatments for several life-threatening viral and inflammatory conditions.

Measuring Recent Performance

• Total revenues reached $7.8 billion for the three months ended June 30, 2026, up 10% year over year.
• Net loss was $10.5 billion for the three months ended June 30, 2026, compared to net income of $2.0 billion in 2025.
• Acquired in-process research and development expenses reached $11.2 billion for the three months ended June 30, 2026.
• Gilead recorded a $1.75 billion charge in June 2026 to account for discontinued lung cancer research.
• Cash and cash equivalents were $3.2 billion as of June 30, 2026.

Focusing on the Future

Gilead is diversifying its business beyond its established HIV and liver disease markets by investing heavily in oncology and inflammation. This transition involves multibillion-dollar acquisitions intended to create a broader range of specialized medicine.